Patents by Inventor Jean Edouard Gairin

Jean Edouard Gairin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6623740
    Abstract: Human melanoma cells bear antigens that are recognized by autologous CD8+ cytotoxic T-lymphocytes. The invention involves the reception of particular peptides analogues of the MZ2-E antigen by HLA molecules. Disclosed herein are peptide analogues of the tumor antigen MZ2-E that have been modified to resist peptidase degradation, and which bind HLA molecules to form a complex whose recognition by specific cytolytic T cells leads to lysis of the complex. The identification by cytolytic T cells of the peptide analogue/HLA complex may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: September 23, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean Edouard Gairin, Maha Ayyoub, Benoit Van Den Eynde, Honoré Mazarguil, Bernard Monsarrat
  • Patent number: 6087441
    Abstract: Human melanoma cells bear antigens that are recognized by autologous CD8+ cytotoxic T-lymphocytes. The invention involves the reception of particular peptides analogues of the MZ2-E antigen by HLA molecules. Disclosed herein are peptide analogues of the tumor antigen MZ2-E that have been modified to resist peptidase degradation, and which bind HLA molecules to form a complex whose recognition by specific cytolytic T cells leads to lysis of the complex. The identification by cytolytic T cells of the peptide analogue/HLA complex may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: July 11, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean Edouard Gairin, Maha Ayyoub, Benoit Van Den Eynde, Honore Mazarguil, Bernard Monsarrat